CENTAURUS suggests early apoB/apoA-1 ratio effect with rosuvastatin

Thursday, April 15th, 2010

Source: MedWire News Treatment for 1 month with rosuvastatin 20 mg decreases the ratio of apolipoprotein (apo)B to A-1 more than does of atorvastatin 80 mg in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS), trial findings suggest. Both statins reduced apoB/apoA-1 ratio to a similar extent at the primary endpoint of 3 months in the […]

FDA approves Crestor for younger patients with familial hypercholesterolemia.

Monday, October 19th, 2009

The AP (10/16) reported that “the Food and Drug Administration approved AstraZeneca PLC’s cholesterol drug Crestor [rosuvastatin] for use by children and teenagers with a genetic disease” called heterozygous familial hypercholesterolemia. The condition “affects 10 million people worldwide, and causes high levels of…LDL cholesterol.” HeartWire (10/16, O’Riordan) reported that “the approval is based on data […]